Cargando…

Emerging Medical Treatment for Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is a common myocardial disease characterized by otherwise unexplained left ventricular hypertrophy. The main cause of disabling symptoms in patients with HCM is left ventricular outflow tract (LVOT) obstruction. This phenomenon is multifactorial, determined both by...

Descripción completa

Detalles Bibliográficos
Autores principales:	Argirò, Alessia, Zampieri, Mattia, Berteotti, Martina, Marchi, Alberto, Tassetti, Luigi, Zocchi, Chiara, Iannone, Luisa, Bacchi, Beatrice, Cappelli, Francesco, Stefàno, Pierluigi, Marchionni, Niccolò, Olivotto, Iacopo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957690/ https://www.ncbi.nlm.nih.gov/pubmed/33804412 http://dx.doi.org/10.3390/jcm10050951

Ejemplares similares

Stage-specific therapy for hypertrophic cardiomyopathy
por: Argirò, Alessia, et al.
Publicado: (2023)

Paradoxical prolongation of QT interval during exercise in patients with hypertrophic cardiomyopathy: cellular mechanisms and implications for diastolic function
por: Coppini, Raffaele, et al.
Publicado: (2022)

Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside
por: Palandri, Chiara, et al.
Publicado: (2022)

Genetic Testing and Counselling in Hypertrophic Cardiomyopathy: Frequently Asked Questions
por: Girolami, Francesca, et al.
Publicado: (2023)

Real-World Use and Predictors of Response to Disopyramide in Patients with Obstructive Hypertrophic Cardiomyopathy
por: Maurizi, Niccolò, et al.
Publicado: (2023)

Microvascular Dysfunction in Hypertrophic Cardiomyopathy
por: Pelliccia, Francesco, et al.
Publicado: (2022)

Diagnostic and prognostic electrocardiographic features in patients with hypertrophic cardiomyopathy
por: Bernardini, Andrea, et al.
Publicado: (2023)

Hypertrophic cardiomyopathy: The need for randomized trials
por: Olivotto, Iacopo, et al.
Publicado: (2013)

Cardiogenic Shock in Obstructive Hypertrophic Cardiomyopathy Plus Apical Ballooning: Management With VA-ECMO and Myectomy
por: Caniato, Flavia, et al.
Publicado: (2021)

Genetic profile of hypertrophic cardiomyopathy in Tunisia: Is it different?
por: Jaafar, Nawel, et al.
Publicado: (2015)

Metabolomics Fingerprint Predicts Risk of Death in Dilated Cardiomyopathy and Heart Failure
por: Vignoli, Alessia, et al.
Publicado: (2022)

Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter
por: Masri, Ahmad, et al.
Publicado: (2022)

Factors associated with persistence of symptoms 1 year after COVID-19: A longitudinal, prospective phone-based interview follow-up cohort study
por: Fumagalli, Carlo, et al.
Publicado: (2022)

Effects of myocardial fibrosis assessed by MRI on dynamic left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy: a retrospective database analysis
por: Biagini, Elena, et al.
Publicado: (2012)

Prevalence of anxiety and depression symptoms in a sample of outpatients with ATTR cardiac amyloidosis
por: Smorti, Martina, et al.
Publicado: (2023)

Contemporary Insights Into the Genetics of Hypertrophic Cardiomyopathy: Toward a New Era in Clinical Testing?
por: Mazzarotto, Francesco, et al.
Publicado: (2020)

INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy—a Randomised Intervention Trial with losartan)
por: Olivotto, Iacopo, et al.
Publicado: (2015)

Predicting Mortality Risk in Older Hospitalized Persons With COVID-19: A Comparison of the COVID-19 Mortality Risk Score with Frailty and Disability
por: Fumagalli, Carlo, et al.
Publicado: (2021)

Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy
por: Braunwald, Eugene, et al.
Publicado: (2023)

Genotype-Driven Pathogenesis of Atrial Fibrillation in Hypertrophic Cardiomyopathy: The Case of Different TNNT2 Mutations
por: Pioner, Josè Manuel, et al.
Publicado: (2022)

Plasmatic and myocardial microRNA profiles in patients with Hypertrophic Cardiomyopathy
por: Lombardi, Maria, et al.
Publicado: (2021)

Impact of Demographic Features, Lifestyle, and Comorbidities on the Clinical Expression of Hypertrophic Cardiomyopathy
por: Finocchiaro, Gherardo, et al.
Publicado: (2017)

Mitochondrial Energetics and Ca(2+)-Activated ATPase in Obstructive Hypertrophic Cardiomyopathy
por: Lombardi, Maria, et al.
Publicado: (2020)

A multidisciplinary case report of multiple myeloma with renal and cardiac involvement: a look beyond amyloidosis
por: Innocenti, Samantha, et al.
Publicado: (2022)

Genetic determinants of clinical phenotype in hypertrophic cardiomyopathy
por: Velicki, Lazar, et al.
Publicado: (2020)

Pattern and degree of left ventricular remodeling following a tailored surgical approach for hypertrophic obstructive cardiomyopathy
por: El-Hamamsy, Ismail, et al.
Publicado: (2012)

Temporal Trend of Age at Diagnosis in Hypertrophic Cardiomyopathy: An Analysis of the International Sarcomeric Human Cardiomyopathy Registry
por: Canepa, Marco, et al.
Publicado: (2020)

The coronary microcirculation in sepsis: not of micro-importance
por: Argirò, Alessia, et al.
Publicado: (2020)

Prognostic Value of Reduced Heart Rate Reserve during Exercise in Hypertrophic Cardiomyopathy
por: Ciampi, Quirino, et al.
Publicado: (2021)

Electrophysiological and Contractile Effects of Disopyramide in Patients With Obstructive Hypertrophic Cardiomyopathy: A Translational Study
por: Coppini, Raffaele, et al.
Publicado: (2019)

Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument
por: Reaney, Matthew, et al.
Publicado: (2022)

Myosins and MyomiR Network in Patients with Obstructive Hypertrophic Cardiomyopathy
por: Foglieni, Chiara, et al.
Publicado: (2022)

Histopathology of the Mitral Valve Residual Leaflet in Obstructive Hypertrophic Cardiomyopathy
por: Troy, Aaron L., et al.
Publicado: (2023)

Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy
por: Marston, Nicholas A, et al.
Publicado: (2021)

The natural history of hypertrophic cardiomyopathy
por: Autore, Camillo, et al.
Publicado: (2020)

Clinical Phenotype and Outcome of Hypertrophic Cardiomyopathy Associated With Thin-Filament Gene Mutations
por: Coppini, Raffaele, et al.
Publicado: (2014)

Late sodium current inhibitors to treat exercise‐induced obstruction in hypertrophic cardiomyopathy: an in vitro study in human myocardium
por: Ferrantini, Cecilia, et al.
Publicado: (2018)

Sex‐Related Differences in Genetic Cardiomyopathies
por: Argirò, Alessia, et al.
Publicado: (2022)

RNA‐seq profiling reveals different pathways between remodeled vessels and myocardium in hypertrophic cardiomyopathy
por: Pisano, Annalinda, et al.
Publicado: (2022)

Defining the diagnostic effectiveness of genes for inclusion in panels: the experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center
por: Mazzarotto, Francesco, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ftsk6qjpjg671n763ba20bba9t